exogenous TCR or CAR, 5, 6 has been acknowledged to have clinical relevance. T cells including IFN-c-producing Th1, IL-4-producing Th2, IL- 17-producing Th17, and Tfh in the context of in vivo environments. 7, 8 These effector cells further give rise to long-lasting memory T cells that are required for a durable response against the cancer. 
| IL-6 SIGNALIN G AS A POOR PR OGNOSTIC FACTOR
Chronic inflammation is recognized as a tumor hallmark that is implicated in tumorigenesis and tumor progression. [10] [11] [12] IL-6, one of the proinflammatory cytokines, is involved in cancer progression. 11 Systemically elevated levels of IL-6 have been observed in patients with various types of cancer such as renal cell carcinoma, 12,13 melanoma, 14 ovarian, 15 colorectal, 16 and head and neck cancer, 17 or in patients with cachexia or wasting syndrome. 12 Of note, IL-6 is known as a poor prognostic factor because elevated levels of IL-6 are inversely proportional to survival rates of cancer patients. 14, 18 For a long time, the main focus has been on the direct effects of IL-6 signaling to tumor cells through at least three major signaling pathways: JAK2/STAT3, Ras/MAPK, and PI3K/Akt cascades, which are attributed to expansion and survival of tumor cells, neo-angiogenesis, and inflammation. 11, 19, 20 The pro-tumorigenic role of IL-6 in cancer patients is complex because IL-6 exerts multiple effects not only on tumor cells, and its action is mediated in autocrine and paracrine ways. [18] [19] [20] In addition to tumor cells, IL-6 can be secreted from myeloid cells such as macrophages, 20 DC, 21 and MDSC, 22 and other tumor-associated stroma such as cancer-associated fibroblasts, 23 endothelial, 24 or senescent cells. 25 These cells collaborate with tumors to establish an environment that amplifies spatial and temporal availability of IL-6 signaling in tumor-bearing animals ( Figure 1 ).
Generally, IL-6 binds with a heterotrimeric surface receptor consisting of IL-6Ra and signal-transducing component, gp130. However, even in cells lacking surface IL-6R expression, a soluble form of IL-6R
(soluble IL-6R; sIL-6R) can mediate IL-6 signaling termed as "IL-6
trans-signaling" through the formation of functional multi-molecular complexes of IL-6/sIL-6R with membrane-bound gp130. 26 In addition to IL-6, elevated levels of sIL-6R have been proposed as a poor prognostic factor in patients with certain types of cancer, 27 because they promote IL-6 stabilization and amplify IL-6 signaling through protecting IL-6 from rapid degradation in vivo. 26 34 and in patient survival. 35 Indeed, an adoptive transfer of tumor-specific activated CD4 + T cells led to regression of melanoma in patients. 6 The potent anti-tumor activity | 39 which also amplify the immune-suppressive effects, and limit the anti-tumor T-cell responses (Figure 1) . From a different perspective, it is very likely that Th2-biased differentiation of IL-6-sensitized CD4 + T cells contributes to the skewing toward the pro-tumorigenic M2 macrophages through IL-4 production. 42 Consequently, IL-6 serves as a critical factor that mediates a mutually interrelated immune-suppressive loop among T cells, myeloid cells, and tumor cells to exacerbate tumor progression (Figure 1 ).
This supports the notion that dysregulated inflammation in cancer patients is favorable to tumor progression.
| INFLAMMATION-PRON E ENVIRONME NTS TEND TO BE IMMUNE-SUPPRESSIVE
Tumor progression is greatly contingent on inflammatory status altered by inherent physical conditions. 11, 25, 32 It is conceivable that T-cell-mediated anti-tumor immunity is affected not only by tumorinitiated immune suppression, but also by local or systemic environmental cues such as elevated IL-6. In healthy young adults, the concentration of IL-6 is quite low or undetectable. However, a circulating level of IL-6 of over 5-10 pg/mL is considered abnormally elevated, 26 which is observed under several environmental conditions such as chronological aging, 25,32 obesity, 11 and fever-range thermal stress. 43 Elderly patients represent a large population of cancer patients and the numbers are expected to increase over the next decades.
Thymic involution with aging, subsequent quantitative decrease of de novo supply, and qualitative dysfunction of T cells are responsible for the age-associated decrease in T-cell immunity. 44, 45 In addition to T-cell intrinsic dysfunction, [44] [45] [46] age-related increases in IL-6 (referred to as inflamm-aging 25, 32 ) should be taken into consideration in 
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